Ballentine Partners’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Ballentine Partners’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$18K	–	393
2018 Q2	$18K	Sell	50,000 -50,000	-50%	-$41K	﹤0.01%	350
2018 Q1	$150K	Buy	100,000 +3,800	+4%	+$6.63K	0.01%	340
2017 Q4	$137K	Buy	96,200 +16,200	+20%	+$26.6K	0.01%	354
2017 Q3	$183K	Buy	80,000 +50,000	+167%	+$66.9K	0.01%	362
2017 Q2	$41K	Buy	+30,000	New	+$43.3K	﹤0.01%	412

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Ballentine Partners's ARLZ Position: Q3 2018 in Review

Ballentine Partners sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 50,000 shares — an estimated $18K sold.

Ballentine Partners first reported a position in ARLZ in Q2 2017 and held it in 5 quarters. The position peaked at $183K in Q3 2017. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Ballentine Partners reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Ballentine Partners sold 50,000 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $18K.
Ballentine Partners first reported a position in Aralez Pharmaceuticals Inc. in Q2 2017 and held it in 5 quarters.
Ballentine Partners's Aralez Pharmaceuticals Inc. position peaked at $183K in Q3 2017.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Ballentine Partners's 13F filing for Q3 2018, filed 30 Oct 2018.